language

Sinopharm’s CNBG Says New Covid-19 Drug Combats Delta, Omicron Variants
Liao Shumin
DATE:  Apr 14 2022
/ SOURCE:  Yicai
Sinopharm’s CNBG Says New Covid-19 Drug Combats Delta, Omicron Variants Sinopharm’s CNBG Says New Covid-19 Drug Combats Delta, Omicron Variants

(Yicai Global) April 14 -- China National Biotec Group said the human immunoglobulin drug that the Sinopharm unit is developing is very effective in neutralizing the delta and omicron variants of the virus that causes Covid-19.

The Beijing-based firm made the announcement on WeChat yesterday, citing the latest clinical test results CNBG scientist Yang Xiaoming and Wuhan Institute of Virology scientist Wang Manli and their teams published in a paper in Advanced Science, an academic periodical.

The intravenous drug, which is expected to be a powerful ally in the battle against Covid-19, uses a specific immunoglobulin made from healthy human plasma containing Covid-19 antibodies and high-potency SARS-CoV-2 neutralizing antibodies. It is the world’s first such drug.

The jab was approved for clinical tests last September, and trials are now being carried out in the United Arab Emirates. So far, CNBG has developed four vaccines, three diagnostic reagents, and two drug therapies for Covid-19.

CNBG's first inactivated Covid-19 vaccine was approved for conditional sale in China at the end of 2020, becoming the first of its kind in the county. It was also certified for emergency use by the World Health Organization on May 7 last year.

Editor: Futura Costaglione

Follow Yicai Global on
Keywords:   Hyperimmune Globulin,CNBG